Korean drug maker Celltrion has announced that it ready to begin phase 1 and phase 3 clinical trials for CT-P17, a proposed adalimumab biosimilar referencing AbbVie’s Humira, which is used to treat a variety inflammatory diseases. The trials will be conducted simultaneously at 75 sites in 8 nations in the European region including the United Kingdom, and the company indicates that the trials will be completed by 2020.
Korean drug maker Celltrion has announced that it ready to begin phase 1 and phase 3 clinical trials for CT-P17, a proposed adalimumab biosimilar referencing AbbVie’s Humira, which is used to treat a variety inflammatory diseases. The trials will be conducted simultaneously at 75 sites in 8 nations in the European region including the United Kingdom, and the company indicates that the trials will be completed by 2020.
According to the biosimilar developer, the proposed product contains a higher-concentration formulation of adalimumab than other biosimilars that are currently approved, a fact that Celltrion hopes will differentiate its product from competitive biosimilars.
Novel formulations of biosimilars are becoming a hallmark of Celltrion’s approach; recently, the company announced that a new formulation of its infliximab biosimilar (sold as Inflectra in the United States and as Remsima in the European Union) that is intended for subcutaneous rather than intravenous administration has comparable efficacy and safety to the currently authorized product in patients with Crohn disease and rheumatoid arthritis.
Click here to read more about subcutaneous Inflectra.
If eventually approved, Celltrion’s product will compete with a growing field of biosimilars referencing the blockbuster Humira; already approved for marketing in the European Union are Amgen’s Amgevita (a molecule also authorized under the brand name Solymbic), Boehringer Ingelheim’s Cyltezo, Samsung Bioepis’ Imraldi, and Sandoz’s Hyrimoz.
The first biosimilar adalimumab products, Imraldi and Amgevita, are expected to launch in the European Union in October 2018, and national health systems, including the United Kingdom’s NHS, are already preparing to begin using the products.
In the United States, the FDA has approved 2 biosimilar adalimumab products (Cyltezo and Amgen’s Amjevita, which is given a slightly altered spelling for the US market), but no biosimilar adalimumab is set to launch prior to 2023 as a result of legal settlements concerning AbbVie’s patents on the reference product.
Celltrion also reports that its pipeline contains biosimilar candidates of bevacizumab, etanercept, cetuximab, and palivizumab, as well as innovator antibodies targeting influenza, breast cancer, hepatitis B, and rabies.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.